MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581144 | Name: Phenylbutazone sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Phenylbutazone sodium has anti-inflammatory effects.

Chemical Structure

Phenylbutazone sodium
Phenylbutazone sodium
CAS#129-18-0 (sodium)

Theoretical Analysis

MedKoo Cat#: 581144

Name: Phenylbutazone sodium

CAS#: 129-18-0 (sodium)

Chemical Formula: C19H20N2NaO2

Exact Mass: 331.1422

Molecular Weight: 331.37

Elemental Analysis: C, 68.87; H, 6.08; N, 8.45; Na, 6.94; O, 9.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
70145-60-7 (calcium) 129-18-0 (sodium) 50-33-9 (free form)
Synonym
Phenylbutazone sodium; Phenylbutazone sodium salt; Sodium phenylbutazone; Sodium butazolidine;
IUPAC/Chemical Name
sodium 4-butyl-5-oxo-1,2-diphenyl-2,5-dihydro-1H-pyrazol-3-olate
InChi Key
NNFXVGOLTQESMQ-UHFFFAOYSA-M
InChi Code
InChI=1S/C19H20N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13,22H,2-3,14H2,1H3;/q;+1/p-1
SMILES Code
CCCCC1=C(O[Na])N(C2=CC=CC=C2)N(C3=CC=CC=C3)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 331.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Raidal SL, Hughes KJ, Charman AL, Nielsen SG, Phillips JK, Noble GK. Effects of meloxicam and phenylbutazone on renal responses to furosemide, dobutamine, and exercise in horses. Am J Vet Res. 2014 Jul;75(7):668-79. doi: 10.2460/ajvr.75.7.668. PubMed PMID: 24959734. 2: BAZZI U, GIANGRASSO F. [Variations in the histological and histochemical findings in the pituitary glands and adrenal cortices of guinea pigs treated with phenylbutazone]. Boll Soc Ital Biol Sper. 1953 Apr;29(4):711-4. Undetermined Language. PubMed PMID: 13106017. 3: FOERSTER W, SZIEGOLEIT W. [On the correlation between the inhibition of active Na transport in erythrocytes and the positive inotropic action of digitalis compounds after phenylbutazone damage]. Experientia. 1962 Dec 15;18:573-5. German. PubMed PMID: 13945701. 4: López Sánchez J, Yañez Marchena G. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison. Arzneimittelforschung. 1983;33(4A):653-6. PubMed PMID: 6349651. 5: Gerken DF, Sams RA. Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. J Pharmacokinet Biopharm. 1985 Oct;13(5):467-76. PubMed PMID: 3834064. 6: EISEN MJ. COMBINED EFFECT OF SODIUM WARFARIN AND PHENYLBUTAZONE. JAMA. 1964 Jul 6;189:64-5. PubMed PMID: 14149032. 7: Santoro MI, Ferreira PC. [Phenylbutazone and its analogs. Synthesis, chemical and pharmaceutical properties]. Rev Farm Bioquim Univ Sao Paulo. 1973 Jul-Dec;11(2):117-41. Review. Portuguese. PubMed PMID: 4612652. 8: Hanada S, Mengardo S, Oga S. Bioavailability and anti-inflammatory effects of phenylbutazone sodium and phenylbutazone calcium in rats. Boll Chim Farm. 1987 May;126(5):203-7. PubMed PMID: 3450309. 9: CHITI E, MALERBA G. [Phenylbutazone and water-electrolyte metabolism; modifications of the electrolytes, sodium potassium and chlorine, after administration of phenylbutazone in normal subjects]. Arch Maragliano Patol Clin. 1955 Jun;10(3):1259-71. Italian. PubMed PMID: 13269250. 10: Alexander F. Effect of phenylbutazone on electrolyte metabolism in ponies. Vet Rec. 1982 Mar 20;110(12):271-2. PubMed PMID: 7080416. 11: de MEDEIROS, RIBEIRO AP, BARROS HS. [Indications for the treatment of thrombophlebitis with phenylbutazone sodium]. Arq Bras Med. 1960 Nov-Dec;50:426-8. Portuguese. PubMed PMID: 14471976. 12: de MEDEIROS, RIBEIRO AP, BARROS HS. [Indications for the treatment of thrombophlebitis with sodium phenylbutazone]. Hospital (Rio J). 1960 Nov;58:973-6. Portuguese. PubMed PMID: 13768827. 13: PERES I. [Phenylbutazone sodium in the treatment of arthroses]. Rev Bras Med. 1961 Mar;18:180-2. Portuguese. PubMed PMID: 14485275. 14: GOSPODINOFF A. [Experimental study of ulcerogenic effect of a new phenylbutazone salt]. Gazz Med Ital. 1957 Mar;116(3):128-31. Italian. PubMed PMID: 13438219. 15: YU TF, BURNS JJ, PATON BC, GUTMAN AB, BRODIE BB. Phenylbutazone metabolites: antirheumatic, sodium-retaining and uricosuric effects in man. J Pharmacol Exp Ther. 1958 May;123(1):63-9. PubMed PMID: 13539792. 16: Ichibagase H, Imamura Y, Kinoshita A, Kojima S. Effects of simultaneous administration of drugs on absorption and excretion. I. Effect of phenylbutazone on absorption and excretion of sodium cyclamate in rabbits. Chem Pharm Bull (Tokyo). 1972 May;20(5):947-52. PubMed PMID: 5055125. 17: Doherty TJ, Andrews FM, Blackford JT, Rohrbach BW, Sandin A, Saxton AM. Effects of lipopolysaccharide and phenylbutazone on gastric contents in the horse. Equine Vet J. 2003 Jul;35(5):472-5. PubMed PMID: 12875325. 18: YU TF, BURNS JJ, DAYTON PG, GUTMAN AB, BRODIE BB. A p-nitro analogue of phenylbutazone possessing potent antirheumatic, sodium retaining and uricosuric properties. J Pharmacol Exp Ther. 1959 Jul;126(3):185-9. PubMed PMID: 13673366. 19: Bakkali A, Corta E, Berrueta LA, Gallo B, Vicente F. Study of the solid-phase extraction of diclofenac sodium, indomethacin and phenylbutazone for their analysis in human urine by liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):139-45. PubMed PMID: 10410936. 20: Dyke TM, Hinchcliff KW, Sams RA. Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses. Equine Vet J. 1999 Jul;31(4):289-95. PubMed PMID: 10454086.